Protara Therapeutics, Inc. (TARA)
3.94
-0.03
(-0.76%)
USD |
NASDAQ |
Sep 04, 16:00
3.95
+0.01
(+0.25%)
After-Hours: 20:00
Protara Therapeutics Research and Development Expense (Quarterly) : 16.88M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.88M |
| March 31, 2026 | 13.47M |
| December 31, 2025 | 13.03M |
| September 30, 2025 | 9.503M |
| June 30, 2025 | 10.67M |
| March 31, 2025 | 9.065M |
| December 31, 2024 | 9.499M |
| September 30, 2024 | 7.986M |
| June 30, 2024 | 6.304M |
| March 31, 2024 | 7.665M |
| December 31, 2023 | 6.381M |
| September 30, 2023 | 6.139M |
| June 30, 2023 | 7.169M |
| March 31, 2023 | 5.066M |
| December 31, 2022 | 4.915M |
| September 30, 2022 | 3.402M |
| June 30, 2022 | 3.031M |
| March 31, 2022 | 5.213M |
| December 31, 2021 | 4.068M |
| September 30, 2021 | 4.093M |
| June 30, 2021 | 5.832M |
| March 31, 2021 | 7.008M |
| December 31, 2020 | 3.620M |
| September 30, 2020 | 2.748M |
| June 30, 2020 | 2.456M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.995M |
| December 31, 2019 | 0.6988M |
| September 30, 2019 | 1.099M |
| June 30, 2019 | 0.9867M |
| March 31, 2019 | 1.078M |
| December 31, 2018 | 2.663M |
| September 30, 2018 | 2.354M |
| June 30, 2018 | 2.76M |
| March 31, 2018 | 4.071M |
| December 31, 2017 | 3.213M |
| September 30, 2017 | 10.34M |
| June 30, 2017 | 3.891M |
| March 31, 2017 | 4.246M |
| December 31, 2016 | 4.437M |
| September 30, 2016 | 4.842M |
| June 30, 2016 | 5.241M |
| March 31, 2016 | 4.349M |
| December 31, 2015 | 3.58M |
| September 30, 2015 | 3.078M |
| June 30, 2015 | 3.09M |
| March 31, 2015 | 2.633M |
| December 31, 2014 | 1.874M |
| September 30, 2014 | 1.773M |
| June 30, 2014 | 1.596M |
| March 31, 2014 | 1.189M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 0.917M |
| Summit Therapeutics, Inc. | 157.73M |
| Kezar Life Sciences, Inc. | 1.545M |
| Clene, Inc. | 3.135M |